Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia

Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia

Abstract: We conducted a multicenter, open-label, randomized phase 2 study to assess the efficacy of nivolumab (Nivo) as maintenance therapy for patients with acute myeloid leukemia (AML) in first complete remission (CR) or CR with incomplete hematologic recovery who were not candidates for stem cel...

Full description

Saved in:
Bibliographic Details
Main Authors: Athalia R. Pyzer, Laura W. Dillon, Elad Sharon, Theodore G. Karrison, Yuanyuan Zha, Noreen Fulton, Gege Gui, Georgia Andrew, Howard Streicher, Kendra Sweet, George Yaghmour, Jane Jijun Liu, Brian A. Jonas, Aaron D. Schimmer, Steven Grant, Amer M. Zeidan, Gerhard C. Hildebrandt, Christopher H. Lowrey, Ryan J. Mattison, Neil Palmisiano, Amandeep Salhotra, Dimitrios Tzachanis, Maria R. Baer, Tara L. Lin, Prapti Patel, Helen Chen, Walter M. Stadler, Olatoyosi Odenike, Richard A. Larson, Thomas F. Gajewski, Christopher S. Hourigan, Wendy Stock, Hongtao Liu
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S247395292500103X
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract: We conducted a multicenter, open-label, randomized phase 2 study to assess the efficacy of nivolumab (Nivo) as maintenance therapy for patients with acute myeloid leukemia (AML) in first complete remission (CR) or CR with incomplete hematologic recovery who were not candidates for stem cell transplant. Patients were stratified and randomized to observation (Obs) or Nivo (3 mg/kg IV every 2 weeks for 46 doses). The primary end point was progression-free survival (PFS) defined as time to disease relapse or death due to any reason. Secondary end points included overall survival (OS), and evaluation of adverse events (AEs) after Nivo administration. Eighty patients were enrolled with median duration of follow-up of 24 months (33 months among survivors). PFS was 13.2 months in the Nivo arm and 10.9 months in the Obs arm. Overall PFS curves were not statistically significantly different. The median OS was 53.9 months in the Nivo arm and 30.9 months in the Obs arm. There were more AEs of any type (regardless of attribution) on the Nivo arm; 27 patients (71%) on the Nivo arm had a grade ≥3 AE compared with 5 patients (12%) on the Obs arm (P < .001). Nivo maintenance after AML chemotherapy failed to improve the PFS and OS in this randomized phase 2 study. There were increased AEs and serious AEs (SAEs) with Nivo, but these AEs and SAEs were expected and manageable. This trial was registered at www.ClinicalTrials.gov as #NCT02275533.
ISSN:2473-9529

Similar Items